• Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis
  • Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests
  • EMA Accepts Humira and Remicade Biosimilars for Regulatory Review
  • DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds
  • Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs
  • Learning Sessions Help Rheumatologists Take Better Care of RA Patients, Study Says
  • Potential Treatment Sirukumab Up Before FDA and EMA with High Expectations, J&J Reports
  • Can-Fite Files Clinical Trial Application in Canada for Piclidenoson to Treat RA
  • Biosimilar CT-P13 Can Safely Replace Much More Expensive Remicade as RA Treatment, Study Finds
  • Researchers Uncover Gene Variations Linked to RA, Other Immune Diseases
  • Phase 3 Trial Finds Kevzara Superior to Humira, and Just as Safe, in Treating Rheumatoid Arthritis
  • Despite Treatment, 80% of RA Patients Report ‘Life-Altering’ Pain Weekly or Even Daily, Survey Finds